Crestor Tablet, Film Coated
Product Images NDC 0310-7580

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Crestor (NDC 0310-7580). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg 90 Tablet Bottle Label

Label for Crestor rosuvastatin calcium 10 mg film-coated tablets, containing 90 tablets. The label shows the NDC 0310-7570-90 and indicates the product is manufactured for AstraZeneca Pharmaceuticals LP. It lists IPR Pharmaceuticals, Inc. in Canovanas, PR, as the manufacturer and states the product is made in Belgium. AstraZeneca logo is visible.*

FDA Label Image

40_mg_bottle_label (40 mg Bottle Label)

Crestor 40 mg tablets packaging label showing the brand name, generic name rosuvastatin calcium, dosage strength 40 mg, quantity of 30 tablets, and manufacturer AstraZeneca Pharmaceuticals LP. The label includes the NDC number 0310-7590-30 and manufacturing details with a purple AstraZeneca logo.*

FDA Label Image

5 mg 90 Tablet Bottle Label

Crestor 5 mg tablets packaging label showing rosuvastatin calcium as the active ingredient. The label indicates it contains 90 film-coated tablets, is Rx only, and is manufactured for AstraZeneca Pharmaceuticals LP by IPR Pharmaceuticals, Inc. The label features the AstraZeneca logo and mentions the product is made in Belgium.*

FDA Label Image

Figure_1 (Figure 1)

Box plot chart comparing the percent change from baseline in LDL-C levels for different doses of Crestor (rosuvastatin) alongside atorvastatin, simvastatin, and pravastatin. The x-axis lists doses in mg, and the y-axis shows percent change ranging approximately from 0 to -75%.*

FDA Label Image

Figure_2 (Figure 2)

A line graph comparing cumulative incidence percentages over approximately 5 years between Rosuvastatin (solid line) and placebo (dotted line). The graph shows a lower cumulative incidence for Rosuvastatin. A hazard ratio (HR) of 0.56 with 95% confidence interval (0.46-0.69) and a p-value <0.001 are displayed. Numbers at risk for RSV and placebo groups are listed below the x-axis.*

FDA Label Image

Figure_3 (Figure 3)

A data table presenting the number of cardiovascular events comparing Crestor (Rosuvastatin) 20 mg and placebo 20 mg groups (n=8901 each). It includes event rates per 1000 patient-years, hazard ratios with 95% confidence intervals, p-values, and a hazard ratio plot across multiple endpoints such as primary end point (MCE), cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, hospitalized unstable angina, and arterial revascularization.*

FDA Label Image

Image 01

Label for Crestor 20 mg tablets, film-coated oral tablets containing rosuvastatin calcium. The label indicates a package quantity of 90 tablets and is manufactured for AstraZeneca Pharmaceuticals LP, Wilmington, DE, by IPR Pharmaceuticals, Inc., Canóvanas, PR. The label includes the AstraZeneca logo and notes the product is from Belgium.*

FDA Label Image

Structural_formula (Structural Formula)

Chemical structure of Rosuvastatin calcium, the active ingredient in Crestor tablets. The diagram shows the molecular arrangement including the fluorophenyl group, sulfonyl methyl group, hydroxyl groups, and the calcium ion complex.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.